VERA · Vera Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $215.26M | $126.17M | $78.22M | $68.99M | $45.21M |
| SG&A | $100.22M | $41.00M | $23.79M | $21.91M | $4.04M |
| Total Operating Expenses | $315.47M | $167.17M | $102.01M | $90.90M | $52.24M |
| D&A | $468.0K | $105.0K | - | - | - |
| Operating Income | ($315.47M) | ($167.17M) | ($102.01M) | ($90.90M) | ($52.24M) |
| Interest Expense | $7.53M | $7.63M | $3.79M | $992.0K | $166.0K |
| Income Tax | $1.0K | $1.0K | $1.0K | $1.0K | ($1.0K) |
| Net Income | ($299.62M) | ($152.15M) | ($95.99M) | ($89.06M) | ($53.41M) |
| EPS - Basic | ($4.66) | ($2.75) | ($2.25) | ($2.43) | - |
| EPS - Diluted | ($4.66) | ($2.75) | ($2.25) | ($2.43) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $354.73M | $92.65M | $45.68M | $43.46M | $79.67M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $21.90M | $7.67M | $11.12M | $11.99M | $1.39M |
| Current Assets | $728.88M | $651.22M | $172.02M | $125.70M | $82.54M |
| Total Assets | $734.73M | $655.68M | $175.55M | $131.44M | $83.75M |
| Current Liabilities | $53.45M | $25.37M | $22.30M | $25.60M | $7.69M |
| Long-term Debt | $74.84M | $50.69M | $49.88M | $24.81M | $0 |
| Total Liabilities | $130.21M | $78.53M | $73.86M | $54.53M | $14.16M |
| Stockholders' Equity | $604.52M | $577.15M | $101.69M | $76.91M | $69.59M |
| Retained Earnings | ($760.87M) | ($461.25M) | ($309.10M) | ($213.11M) | ($124.06M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($241.10M) | ($134.68M) | ($92.18M) | ($67.60M) | ($34.81M) |
| Investing Cash Flow | $194.29M | ($425.03M) | ($39.43M) | ($70.55M) | ($42.0K) |
| Financing Cash Flow | $308.90M | $606.67M | $133.54M | $101.93M | $85.29M |
| CapEx | $630.0K | $972.0K | $63.0K | $0 | $99.0K |
| Free Cash Flow | ($241.73M) | ($135.65M) | ($92.24M) | ($67.60M) | ($34.91M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | 0.81 | 0.89 | 0.96 | 0.76 | 0.65 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -40.8% | -23.2% | -54.7% | -67.8% | -63.8% |
| Return on equity | -49.6% | -26.4% | -94.4% | -115.8% | -76.8% |
| Return on invested capital | -36.7% | -21.0% | -53.2% | -70.6% | -59.3% |
| Liquidity | |||||
| Current ratio | 13.64 | 25.67 | 7.71 | 4.91 | 10.73 |
| Quick ratio | 13.64 | 25.67 | 7.71 | 4.91 | 10.73 |
| Cash ratio | 6.64 | 3.65 | 2.05 | 1.70 | 10.36 |
| Leverage | |||||
| Debt / Equity | 0.12 | 0.09 | 0.49 | 0.32 | 0.00 |
| Debt / Assets | 0.10 | 0.08 | 0.28 | 0.19 | 0.00 |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -41.9x | -21.9x | -26.9x | -91.6x | -314.7x |
| Equity multiplier | 1.22 | 1.14 | 1.73 | 1.71 | 1.20 |
| Liabilities / Assets | 0.18 | 0.12 | 0.42 | 0.41 | 0.17 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 5.4x | 4.1x | 6.5x | 3.4x | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -88.7% | -63.9% | -12.2% | -74.0% | - |
| Net income growth (YoY) | -96.9% | -58.5% | -7.8% | -66.7% | - |
| EPS growth (YoY) | -69.5% | -22.2% | 7.4% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -78.2% | -47.1% | -36.5% | -93.6% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 4.7% | 467.6% | 32.2% | 10.5% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Vera Therapeutics against the 5 most active filers in the same SIC group.